Citations

Clear

3030 citation(s) found for "Susan, M".

Pulmonary hypertension due to interstitial lung disease or chronic obstructive pulmonary disease: a patient experience study of symptoms and their impact on quality of life
DuBrock, Hilary M. , Nathan, Steven D. , Mathai, Stephen C. , Classi, Peter, Nelsen, Andrew C. , Olayinka‐Amao, Bimpe, Norcross, Lindsey , Martin, Susan , Martin, Susan A , DuBrock, Hilary M , Mathai, Stephen C , Reeve, Bryce B. , Kolaitis, Nicholas A

Mayo Clinic

Pulmonary Circulation | March 16, 2021 | Volume: 11 | Issue: 2 | Pages: 1-9

10.1177/20458940211005641 | PMID 33868642 Get It

Pulmonary hypertension resulting from chronic lung disease such as chronic obstructive pulmonary disease and interstitial lung disease is categorized by the World Health Organization as Group 3 pulmonary hypertension. To identify the symptoms and impacts of World Health Organization Group 3 pulmonary hypertension and to capture data related to the patient experience of this disease, qualitative research interviews were undertaken with 3 clinical experts and 14 individuals with pulmonary hypertension secondary to chronic obstructive pulmonary disease or interstitial lung disease. Shortness of breath, fatigue, cough, and swelling were the most frequently reported symptoms of pulmonary hypertension due to chronic obstructive pulmonary disease or interstitial lung disease, and shortness of breath was further identified as the single most bothersome symptom for most patients (71.4%). Interview participants also described experiencing a number of impacts related to pulmonary hypertension and pulmonary hypertension symptoms, including limitations in the ability to perform activities of daily living and impacts on physical functioning, family life, and social life as well as emotional impacts, which included frustration, depression, anxiety, isolation, and sadness. Results of these qualitative interviews offer an understanding of the patient experience of pulmonary hypertension due to chronic obstructive pulmonary disease or interstitial lung disease, including insight into the symptoms and impacts that are most important to patients in this population. As such, these results may help guide priorities in clinical treatment and assist researchers in their selection of patient‐reported outcome measures for clinical trials in patients with pulmonary hypertension due to chronic obstructive pulmonary disease or interstitial lung disease.
Bone Aging, Cellular Senescence, and Osteoporosis
Pignolo, Robert J. , Law, Susan F., Chandra, Abhishek , Chandra, Abhishek

Mayo Clinic

JBMR Plus | March 15, 2021 | Volume: 5 | Issue: 4 | Pages: No page available

10.1002/jbm4.10488 | PMID 33869998 Get It

ABSTRACT Changes in aging bone that lead to osteoporosis are mediated at multiple levels, including hormonal alterations, skeletal unloading, and accumulation of senescent cells. This pathological interplay is superimposed upon medical conditions, potentially bone‐wasting medications, modifiable and unmodifiable personal risk factors, and genetic predisposition that accelerate bone loss with aging. In this study, the focus is on bone hemostasis and its dysregulation with aging. The major physiological changes with aging in bone and the role of cellular senescence in contributing to age‐related osteoporosis are summarized. The aspects of bone aging are reviewed including remodeling deficits, uncoupling phenomena, inducers of cellular senescence related to bone aging, roles of the senescence‐associated secretory phenotype, radiation‐induced bone loss as a model for bone aging, and the accumulation of senescent cells in the bone microenvironment as a predominant mechanism for age‐related osteoporosis. The study also addresses the rationale and potential for therapeutic interventions based on the clearance of senescent cells or suppression of the senescence‐associated secretory phenotype. © 2021 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.
Abstract P55: Retinal Microvascular Parameters Predict Retinal Amyloid Burden and Co-Jointly Predict Verbal Memory
Dumitrascu, Oana M. , Rosenberry, Ryan , Khansari, Maziyar M. , Torbati, Tania , Sherman, Dale , Sherzai, Ayesha , Sheyn, Julia, Johnson, Kenneth G. , Czeszynki, Alan, Verdooner, Steven, Black, Keith L. , Koronyo, Yosef, Lyden, Patrick D. , Shi, Yonggang , Johnson, Kenneth, Frautschy, Sally A. , Koronyo‐Hamaoui, Maya , Cheng, Susan , Black, Keith L

Mayo Clinic

Stroke | March 11, 2021 | Volume: 52 | Issue: Suppl_1 | Pages: No page available

10.1161/str.52.suppl_1.p55 Get It

Introduction: Retinal vascular features predict cognitive performance and retinal imaging is a non-invasive tool to study brain health. Patients with Alzheimer’s disease (AD)-related cognitive disorders exhibit both retinal vascular abnormalities and intraretinal accumulation of amyloid-beta (Aβ) plaque. Curcumin-enhanced retinal fluorescence imaging (CRFI) was recently translated as a safe imaging tool for retinal Aβ plaque quantification. In this study, we sought to determine whether and which retinal arterial and venous parameters are predictive of retinal Aβ burden and cognitive Z-scores. Methods: We used scanning laser ophthalmoscopy with RetiaTM (Centervue, Inc) to obtain CRFI in a cohort of patients with cognitive decline. Retinal blood vessels were segmented in a predefined circumpapillary region of interest. For each centerline, vessel tortuosity index (VTI), vessel inflection index (VII), and branching angle (VBA) were quantified, independently for arteries and veins. Additionally, we automatically quantified retinal amyloid count in the supero-temporal quadrant and its subregions: posterior pole (PP), proximal mid-periphery (PMP), and distal mid-periphery (DMP). All quantifications were done blinded to the subjects’ clinical characteristics. Linear regression models were used to assess the correlations between retinal vascular and amyloid parameters. Results: 29 subjects (55% female, mean age 64±6 years) were included in the analysis: 11 had normal cognition, 16 mild cognitive impairment and 2 probable AD. Venous VTI was the only vascular parameter significantly different across levels of Clinical Dementia Rate scores and between cognitively normal and impaired. Venous VBA was a significant predictor of DMP amyloid count (p=0.03). Arterial VII significantly predicted PP amyloid count (p=0.02). VBA predicted Wechsler Adult Intelligence Scale Z-score (p=0.08). The combined VTI-PMP amyloid index significantly predicted Wechsler Memory Scale, California Verbal Learning Test and SF-36 mental component score Z-scores (p<0.05). Conclusion: Retinal venous tortuosity discriminates across cognitive scores and in combination with PMP amyloid count may predict verbal memory and related quality-of-life scores.
Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients
Macauda, Angelica , Piredda, Chiara , Clay‐Gilmour, Alyssa , Sáinz, Juan , Buda, Gabriele , Markiewicz, Mirosław , Barington, Torben , Ziv, Elad , Hildebrandt, Michelle A.T. , Belachew, Alem A. , Várkonyi, Judit , Prejzner, Witold , Druzd‐Sitek, Agnieszka , Spinelli, John J. , Andersen, Niels Frost, Dudziński, Marek , Martínez‐López, Joaquín , Iskierka‐Jazdzewska, Elżbieta , Mazur, Grzegorz , Ebbesen, Lene Hyldahl, Rymko, Marcin , Subocz, Edyta , Reis, Rui Manuel , García‐Sánz, Ramón , Suska, Anna , Haastrup, Eva, Zawirska, Daria , Grząśko, Norbert , Kruszewski, Marcin , Dutka, Magdalena , Camp, Nicola J. , Waller, Rosalie, Pelosini, Matteo , Raźny, Małgorzata , Abildgaard, Niels , Wątek, Marzena , Brown, Elizabeth E. , Berndt, Sonja I. , Butrym, Aleksandra , Vachon, Celine M. , Gemignani, Federica , Campa, Daniele , Martinez-Lopez, Joaquin , Waller, Rosalie G. , Griffin, R. L. , Canzian, Federico , Campa, Daniele , Martinez-Lopez, Joaquin , Butrym, Aleksandra , Reis, Rui Manuel , Garcia-Sanz, Ramon , Ziv, Elad , Waller, Rosalie G , Rymko, Marcin , Subocz, Edyta , Tomczak, Waldemar , Sainz, Juan , Watek, Marzena , Iskierka-Jazdzewska, Elżbieta , Martinez-Lopez, Joaquin , Mazur, Grzegorz , Hildebrandt, Michelle A T , Markiewicz, Miroslaw , Macauda, Angelica , Griffin, Rosalie , Hofmann, Jonathan N. , Milne, Roger L. , Giles, Graham G. , Jamroziak, Krzysztof , Vangsted, Annette Juul , Dumontet, Charles , Tomczak, Waldemar , Marques, Herlander , Jurczyszyn, Artur , Vachon, Celine M. , Norman, Aaron D. , Slager, Susan L. , Canzian, Federico

Mayo Clinic

International Journal of Cancer | March 6, 2021 | Volume: 149 | Issue: 2 | Pages: 327-336

10.1002/ijc.33547 | PMID 33675538 Get It

AbstractGene expression profiling can be used for predicting survival in multiple myeloma (MM) and identifying patients who will benefit from particular types of therapy. Some germline single nucleotide polymorphisms (SNPs) act as expression quantitative trait loci (eQTLs) showing strong associations with gene expression levels. We performed an association study to test whether eQTLs of genes reported to be associated with prognosis of MM patients are directly associated with measures of adverse outcome. Using the genotype‐tissue expression portal, we identified a total of 16 candidate genes with at least one eQTL SNP associated with their expression with P < 10−7 either in EBV‐transformed B‐lymphocytes or whole blood. We genotyped the resulting 22 SNPs in 1327 MM cases from the International Multiple Myeloma rESEarch (IMMEnSE) consortium and examined their association with overall survival (OS) and progression‐free survival (PFS), adjusting for age, sex, country of origin and disease stage. Three polymorphisms in two genes (TBRG4‐rs1992292, TBRG4‐rs2287535 and ENTPD1‐rs2153913) showed associations with OS at P < .05, with the former two also associated with PFS. The associations of two polymorphisms in TBRG4 with OS were replicated in 1277 MM cases from the International Lymphoma Epidemiology (InterLymph) Consortium. A meta‐analysis of the data from IMMEnSE and InterLymph (2579 cases) showed that TBRG4‐rs1992292 is associated with OS (hazard ratio = 1.14, 95% confidence interval 1.04‐1.26, P = .007). In conclusion, we found biologically a plausible association between a SNP in TBRG4 and OS of MM patients.
Neurologic Involvement in Children and Adolescents Hospitalized in the United States for COVID-19 or Multisystem Inflammatory Syndrome
LaRovere, Kerri L. , Riggs, Becky J. , Young, Cameron C. , Newhams, Margaret M. , Maamari, Mia , Walker, Tracie C. , Singh, Aalok R. , Dapul, Heda , Hobbs, Charlotte V. , McLaughlin, Gwenn E., Maddux, Aline B. , Clouser, Katharine N. , Rowan, Courtney M. , McGuire, John K. , Gertz, Shira J. , Muñoz, Álvaro Coronado , Irby, Katherine , Levy, Emily R. , Staat, Mary Allen , Feldstein, Leora R. , Halasa, Natasha , Hall, Mark W. , Kong, Michele , Carroll, Christopher L. , Schuster, Jennifer E. , Doymaz, Sule , Loftis, Laura L. , Tarquinio, Keiko M. , Babbitt, Christopher , Nofziger, Ryan A. , Kleinman, Lawrence C. , Keenaghan, Michael , Spinella, Philip C. , Hume, Janet R. , Wellnitz, Kari , Mack, Elizabeth H. , Flori, Heidi R. , Patel, Manish M. , Randolph, Adrienne G. , Investigators, Overcoming COVID-19, Name, First Name and Middle Initial Last, Gaspers, Mary Glas , Typpo, Katri , Sanders, Ronald C., Schwarz, Adam J. , Harvey, Helen , Mourani, Peter M. , Coates, Bria M. , Bhoojhawon, Guru , Havlin, Kevin , Sullivan, Janice E, Bradford, Tamara T. , Lipton, Susan V., Chen, Sabrina , Kücükak, Suden, Carroll, Ryan W. , Fernandes, Neil D. , Yager, Phoebe H. , Marohn, Kimberly L, Heidemann, Sabrina M. , Cullimore, Melissa L. , Horwitz, Steven M. , Walsh, Rowan, Soma, Vijaya L, Gillen, Jennifer , Zackai, Sheemon, Ackerman, Kate G. , Cholette, Jill M., Hymes, Saul , Overby, Philip , Schwartz, Stephanie P. , Lansell, Amanda , Koncicki, Monica L. , Carcillo, Joseph A. , Bowens, Cindy , Crandall, Hillary , Smith, Lincoln , Cengiz, Pelin , Levy, Emily R , Young, Cameron C , Randolph, Adrienne G , Spinella, Philip C , Kong, Michele , Hume, Janet R , Hobbs, Charlotte V , Maddux, Aline B , Staat, Mary A , Gertz, Shira J , Schwartz, Stephanie P , Hymes, Saul R , Poussaint, Tina Young , Son, Mary Beth F. , Fitzgerald, Julie C. , Shein, Steven L. , Thomas, Neal J. , Tenforde, Mark W. , Giuliano, John S. , Cvijanovich, Natalie Z , Michelson, Kelly Nicole , Investigators, Overcoming COVID-19, Zinter, Matt S. , Montgomery, Vicki , Sullivan, Janice E, Bembea, Melania M. , Graciano, Ana Lía , Newburger, Jane W. , Marohn, Kimberly L, McCulloh, Russell J. , Li, Simon , Ratner, Adam J. , Harwayne‐Gidansky, Ilana , Fink, Ericka L. , Kimura, Dai

Mayo Clinic

JAMA Neurology | March 5, 2021 | Volume: 78 | Issue: 5 | Pages: 536

10.1001/jamaneurol.2021.0504 | PMID 33666649 Get It

Automated seizure detection using wearable devices: A clinical practice guideline of the International League Against Epilepsy and the International Federation of Clinical Neurophysiology
Wiebe, Samuel , Jeppesen, Jesper , Tatum, William O. , Brázdil, Milan , Wang, Yuping , Herman, Susan T. , Ryvlin, Philippe , Beniczky, Sándor , Wiebe, Samuel , Jeppesen, Jesper , Tatum, William O , Brazdil, Milan , Ryvlin, Philippe

Mayo Clinic

Epilepsia | March 5, 2021 | Volume: 62 | Issue: 3 | Pages: 632-646

10.1111/epi.16818 | PMID 33666944 Get It

Abstract The objective of this clinical practice guideline (CPG) is to provide recommendations for healthcare personnel working with patients with epilepsy on the use of wearable devices for automated seizure detection in patients with epilepsy, in outpatient, ambulatory settings. The Working Group of the International League Against Epilepsy (ILAE) and the International Federation of Clinical Neurophysiology (IFCN) developed the CPG according to the methodology proposed by the ILAE Epilepsy Guidelines Working Group. We reviewed the published evidence using The Preferred Reporting Items for Systematic Review and Meta‐Analysis (PRISMA) statement and evaluated the evidence and formulated the recommendations following the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. We found high level of evidence for the accuracy of automated detection of generalized tonic‐clonic seizures (GTCS) and focal‐to‐bilateral tonic‐clonic seizures (FBTCS) and recommend the use of wearable automated seizure detection devices for selected patients when accurate detection of GTCS and FBTCS is recommended as a clinical adjunct. We also found a moderate level of evidence for seizure types without GTCS or FBTCS. However, it was uncertain whether the detected alarms resulted in meaningful clinical outcomes for the patients. We recommend using clinically validated devices for automated detection of GTCS and FBTCS, especially in unsupervised patients, where alarms can result in rapid intervention (weak/conditional recommendation). At present, we do not recommend clinical use of the currently available devices for other seizure types (weak/conditional recommendation). Further research and development are needed to improve the performance of automated seizure detection and to document their accuracy and clinical utility.
High-Density EEG in Current Clinical Practice and Opportunities for the Future
Stoyell, Sally M. , Dobrota, Mary-Ann, Chinappen, Dhinakaran M. , Mintz, Mark , Brinkmann, Benjamin H. , Herman, Susan T. , Peters, Jurriaan M. , Seeck, Margitta , Hämäläinen, Matti , Chu, Catherine J. , Brinkmann, Benjamin H , Chu, Catherine J , Wilmskoetter, Janina , Bonilha, Leonardo , Vulliémoz, Serge

Mayo Clinic

Journal of Clinical Neurophysiology | March 4, 2021 | Volume: 38 | Issue: 2 | Pages: 112-123

10.1097/wnp.0000000000000807 | PMID 33661787 Get It

Summary: High-density EEG (HD-EEG) recordings use a higher spatial sampling of scalp electrodes than a standard 10-20 low-density EEG montage. Although several studies have demonstrated improved localization of the epileptogenic cortex using HD-EEG, widespread implementation is impeded by cost, setup and interpretation time, and lack of specific or sufficient procedural billing codes. Despite these barriers, HD-EEG has been in use at several institutions for years. These centers have noted utility in a variety of clinical scenarios where increased spatial resolution from HD-EEG has been required, justifying the extra time and cost. We share select scenarios from several centers, using different recording techniques and software, where HD-EEG provided information above and beyond the standard low-density EEG. We include seven cases where HD-EEG contributed directly to current clinical care of epilepsy patients and highlight two novel techniques which suggest potential opportunities to improve future clinical care. Cases illustrate how HD-EEG allows clinicians to: case 1—lateralize falsely generalized interictal epileptiform discharges; case 2—improve localization of falsely generalized epileptic spasms; cases 3 and 4—improve localization of interictal epileptiform discharges in anatomic regions below the circumferential limit of standard low-density EEG coverage; case 5—improve noninvasive localization of the seizure onset zone in lesional epilepsy; cases 6 and 7—improve localization of the seizure onset zone to guide invasive investigation near eloquent cortex; case 8—identify epileptic fast oscillations; and case 9—map language cortex. Together, these nine cases illustrate that using both visual analysis and advanced techniques, HD-EEG can play an important role in clinical management.
Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals
Sims, Emily K. , Bundy, Brian N. , Stier, Kenneth , Serti, Elisavet , Lim, Noha , Long, S. Alice , Geyer, Susan, Moran, Antoinette , Greenbaum, Carla J. , Evans‐Molina, Carmella , Group, Type 1 Diabetes TrialNet Study, DiMeglio, Linda A. , Gitelman, Stephen E. , Gottlieb, Peter A. , Marks, Jennifer B. , Moore, Wayne D. , Rodriguez, Henry , Russell, William E. , Schatz, Desmond , Wherrett, Diane K. , Ziegler, Anette‐Gabriele , Herold, Kevan C , DiMeglio, Linda , Group, Type 1 Diabetes TrialNet Study, Moore, Wayne, Tsalikian, Eva

Mayo Clinic

Science Translational Medicine | March 3, 2021 | Volume: 13 | Issue: 583 | Pages: No page available

10.1126/scitranslmed.abc8980 | PMID 33658358 Get It

Teplizumab treatment of nondiabetic relatives at high risk for T1D induces partially exhausted CD8 + T cells and improves beta cell function.
The Impact of Amyloid Burden and APOE on Rates of Cognitive Impairment in Late Life Depression
Rhodes, Emma , Butters, Meryl A. , Morin, Ruth , Bickford, David , Tosun, Duygu , Gessert, Devon, Rosen, Howie, Aisen, Paul , Raman, Rema , Landau, Susan , Saykin, Andrew J. , Weiner, Michael W. , Nelson, Craig, Mackin, R. Scott , Initiative, on behalf of the Alzheimer’s Disease Neuroimaging, Project, the ADNI Depression, Tosun, Duygu , Saykin, Andrew J , Tosun, Duygu , Insel, Philip S. , Toga, Arthur W. , Jack, Clifford R. , Initiative, on behalf of the Alzheimer’s Disease Neuroimaging, Project, the ADNI Depression

Mayo Clinic

Journal of Alzheimer’s Disease | March 2, 2021 | Volume: 80 | Issue: 3 | Pages: 991-1002

10.3233/jad-201089 | PMID 33682706 Get It

Background: Cognitive impairment (CI) is a key feature of late life depression (LLD), but the contribution of underlying neurodegenerative pathology remains unclear. Objective: To evaluate cognitive dysfunction in LLD relative to a sample of nondepressed (ND) older adults with matched levels of memory impairment and amyloid-β (Aβ) burden. Methods: Participants included 120 LLD and 240 ND older adults matched on age, education, sex, Mini-Mental State Exam, mild cognitive impairment diagnosis, and PET Aβ burden. Results: LLD showed higher rates of impairment relative to ND with 54.6% of the LLD sample demonstrating impairment in at least one cognitive domain compared to 42.9% of controls ( H = 7.13, p = 0.008). LLD had poorer performance and higher rates of impairment on Rey Auditory Verbal Learning Test learning and memory compared to controls. In the overall sample, Aβ positivity was associated with worse performance on Logical Memory I ( p = 0.044), Logical Memory II ( p = 0.011), and Trail Making Test –B ( p = 0.032), and APOE ɛ4 genotype was associated with worse performance on Logical Memory I ( p = 0.022); these relationships did not differ between LLD and ND. Conclusion: LLD showed higher rates of CI driven by focal deficits in verbal learning and memory. Alzheimer’s disease (AD) biomarkers were associated with worse performance on timed set-shifting and story learning and memory, and these relationships were not impacted by depression status. These findings suggest that AD may account for a portion of previously reported multi-domain CI in LLD and highlight the potential for AD to confound studies of cognition in LLD.
The Emerging Global Tobacco Treatment Workforce: Characteristics of Tobacco Treatment Specialists Trained in Council-Accredited Training Programs from 2017 to 2019
Sheffer, Christine E. , Al‐Zalabani, Abdulmohsen H. , Aubrey, Andrée, Bader, Rasha K. , Beltrez, Claribel, Bennett, Susan E., Carl, Ellen , Cranos, Caroline, Darville, Audrey , Greyber, Jennifer , Hawari, Feras , Hynes, V. Barbara, Kotsen, Chris , McConaha, Jamie L. , McCary, Heather, Meade, Crystal D , Messick, Cara, Morgan, Susan , Morris, Cindy W., Retzlaff, Jessica, Santis, Wendy, Short, Etta, Shumaker, Therese, Steinberg, Michael , Wendling, Ann, Al-Zalabani, Abdulmohsen , Bennett, Susan, Messick, Cara , Morris, Cindy W , Steinberg, Michael , Sheffer, Christine E , Karam‐Hage, Maher , Hutcheson, Tresza D. , Leone, Frank T. , Payne, Thomas J.

Mayo Clinic

International Journal of Environmental Research and Public Health | March 2, 2021 | Volume: 18 | Issue: 5 | Pages: 2416

10.3390/ijerph18052416 | PMID 33801227 Get It

Tobacco use is projected to kill 1 billion people in the 21st century. Tobacco Use Disorder (TUD) is one of the most common substance use disorders in the world. Evidence-based treatment of TUD is effective, but treatment accessibility remains very low. A dearth of specially trained clinicians is a significant barrier to treatment accessibility, even within systems of care that implement brief intervention models. The treatment of TUD is becoming more complex and tailoring treatment to address new and traditional tobacco products is needed. The Council for Tobacco Treatment Training Programs (Council) is the accrediting body for Tobacco Treatment Specialist (TTS) training programs. Between 2016 and 2019, n = 7761 trainees completed Council-accredited TTS training programs. Trainees were primarily from North America (92.6%) and the Eastern Mediterranean (6.1%) and were trained via in-person group workshops in medical and academic settings. From 2016 to 2019, the number of Council-accredited training programs increased from 14 to 22 and annual number of trainees increased by 28.5%. Trainees have diverse professional backgrounds and work in diverse settings but were primarily White (69.1%) and female (78.7%) located in North America. Nearly two-thirds intended to implement tobacco treatment services in their setting; two-thirds had been providing tobacco treatment for 1 year or less; and 20% were sent to training by their employers. These findings suggest that the training programs are contributing to the development of a new workforce of TTSs as well as the development of new programmatic tobacco treatment services in diverse settings. Developing strategies to support attendance from demographically and geographically diverse professionals might increase the proportion of trainees from marginalized groups and regions of the world with significant tobacco-related inequities.